Shields C L, Shields J A, Milite J, De Potter P, Sabbagh R, Menduke H
Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, PA 19107.
Ophthalmology. 1991 Nov;98(11):1662-6. doi: 10.1016/s0161-6420(91)32071-2.
A review of 3706 consecutive patients with uveal melanoma revealed that 40 patients (1.1%) were age 20 years or younger at the time of diagnosis. The youngest patient was age 6 years but the majority of patients (78%) were between 15 and 20 years old. The tumor occurred in the iris in 5 cases (12%) and in the posterior uvea in 35 cases (88%). The mean largest tumor dimension and thickness was 10 mm and 5 mm, respectively. In all cases, the diagnosis of uveal melanoma was suspected before referral, and misdirected treatment was avoided. The tumor was initially treated by enucleation in 24 cases (60%), local resection in 7 (18%), plaque radiotherapy in 3 (8%), and observation in 6 (15%). Secondary treatment was required in 7 cases in the form of enucleation (4 cases), ablative laser (1 case), plaque radiotherapy (1 case), and exenteration (1 case). The mean follow-up period was 68 months (median, 48 months) from the time of treatment, and only one patient died of metastases (from a massive ciliochoroidal melanoma 33 months after treatment). The remainder of the group of young patients are alive and healthy. Cumulative survival rates show that 96% of young patients with uveal melanoma survive at the 5-year period.
对3706例连续性葡萄膜黑色素瘤患者的回顾显示,40例(1.1%)患者在诊断时年龄为20岁或更小。最年轻的患者为6岁,但大多数患者(78%)年龄在15至20岁之间。肿瘤发生于虹膜5例(12%),发生于后葡萄膜35例(88%)。肿瘤最大径和厚度的平均值分别为10 mm和5 mm。所有病例在转诊前均怀疑为葡萄膜黑色素瘤,从而避免了治疗方向错误。24例(60%)患者最初接受眼球摘除术治疗,7例(18%)接受局部切除术,3例(8%)接受敷贴放疗,6例(15%)接受观察。7例患者需要二次治疗,形式为眼球摘除术(4例)、消融激光治疗(1例)、敷贴放疗(1例)和眼眶内容剜除术(1例)。从治疗时起,平均随访期为68个月(中位数为48个月),只有1例患者死于转移(治疗后33个月死于巨大睫状体脉络膜黑色素瘤)。其余年轻患者组存活且健康。累积生存率显示,96%的年轻葡萄膜黑色素瘤患者在5年时存活。